巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Tiziana Life Sciences Ltd

    TLSA
    0.740
    0.010
    1.32%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Tiziana Life Sciences Ltd - 延遲價格・最後更新於 16/08 9:30
    最高位
    0.740
    最低位
    0.740
    開市價
    --
    前收市價
    0.750
    成交量(千)
    0.10
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    75.68
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.200 - 0.530
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Tiziana Life Sciences Ltd
    證券代碼
    TLSA.US
    所屬板塊
    Biotechnology
    公司業務
    Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its clinical pipeline includes drug assets for Crohn's Disease, COVID19, Secondary Progressive Multiple Sclerosis, and Hepatocellular Carcinoma. Its development pipeline includes Foralumab, Milciclib, Anti-IL6R, and Others. The company has a single reporting segment, which is the research and development of biotechnological & pharmaceutical products.
    發行量
    102272614
    公司總部
    2 Church Street, Clarendon House
    公司網址
    https://www.tizianalifesciences.com
    公司電郵
    info@tizianalifesciences.com

    美股異動 | Tiziana Life Sciences盤前大漲33% foralumab療法治療多發性硬化症患者中獲得陽性數據

    格隆匯·
    美股異動 | Tiziana Life Sciences盤前大漲33% foralumab療法治療多發性硬化症患者中獲得陽性數據

    美股異動 | Tiziana Life Sciences盤前大漲33% foralumab療法治療多發性硬化症患者中獲得陽性數據

    格隆匯·
    美股異動 | Tiziana Life Sciences盤前大漲33% foralumab療法治療多發性硬化症患者中獲得陽性數據

    關於

    Tiziana Life Sciences Ltd(TLSA.US)所屬的行業板塊為Biotechnology。
    Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its clinical pipeline includes drug assets for Crohn's Disease, COVID19, Secondary Progressive Multiple Sclerosis, and Hepatocellular Carcinoma. Its development pipeline includes Foralumab, Milciclib, Anti-IL6R, and Others. The company has a single reporting segment, which is the research and development of biotechnological & pharmaceutical products.
    詳細公司背景可參考: https://www.tizianalifesciences.com